The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.
about
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidationPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewLentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates.Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in malawian adults on stavudine containing highly active antiretroviral therapyAn analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitorsAnalysis of enzyme kinetic data for mtDNA replication.Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional studySAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.Zidovudine and Lamivudine for HIV Infection.In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionDeterminants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measuresAssociation of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Pharmacologic perspectives for once-daily antiretroviral therapy.Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discriminationApricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyPharmacologic consideration for the use of antiretroviral agents in the elderly.BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue.The impact of pharmacogenetics on HIV therapy.Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.Tempol protects cardiomyocytes from nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.Cardiomyocytes are Protected from Antiretroviral Nucleoside Analog-Induced Mitochondrial Toxicity by Overexpression of PGC-1α.An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network.Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors.Beyond the polymerase-γ theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity.Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
P2860
Q24648578-B09731F8-21B6-4956-97C1-C4D814E5CC79Q26797938-43085A24-A9AC-4F9C-9697-6A6DF469409FQ27318042-F014CFC1-9FCB-4FD5-8292-2ED1FB64F034Q28289556-98E5B7AE-9B4A-4062-899D-56CD8FC70FC8Q28474361-6DF59385-9D97-477F-8839-5765DEA81E12Q33534992-4A6D1E9F-3945-4452-8D10-597462D9616BQ34039225-519A0B57-76D2-47AA-A41F-BBFB512881A4Q34058234-C075E110-1B69-484F-A8F4-8537E95BB04AQ34194561-AC7CF36F-FD78-4880-9724-BA81AE429FC1Q34352006-B09A0845-1833-4A47-B02F-73DA3325DC7DQ34481359-3D482D8A-1466-499F-ADBF-C5471A4924C7Q34529268-055CDEF3-748B-45EF-9D0B-AA21D0C01D71Q34675000-DD9BA017-A0B0-48B7-A84D-ED9637577B3AQ34737674-166C7E2A-AB3E-411B-A24B-2D2873FAF8C0Q34933094-363EA9BD-CF50-4E77-9914-40F8DB862873Q34973688-A96DA2B2-0A73-40FC-983A-318DD28072DAQ35004837-20D5413A-C172-4C4F-908B-0E2B8A617AF4Q35005051-B0EA0F13-D391-4571-A0FC-1CB3F4771EC5Q35915916-C94F549B-2F05-42D7-BB74-7730769D77C2Q36075888-C4954C4A-68EB-4209-904B-22811B0DADBBQ36558253-72223925-E3DD-44AE-A702-115E35BFC18BQ36704152-6C6791D5-F9B6-48A2-AF7B-DC3DB4E6903FQ36836868-A7F0C8E2-C1B3-456F-9D6B-F847E191D438Q36876279-A3DB4E98-5688-423E-925A-3B1485BCBCA7Q36951689-EF51A55F-6F69-4A66-BE7F-027EFDA2A9C8Q37126494-EF656CEB-215D-482E-BB31-905DB7D47F38Q37246452-429A4F13-01F4-4D74-AA8B-9891D56BB405Q37251569-C403F8B7-0BF7-42C7-B7D2-84F0F61F2885Q37277510-252A991C-BA47-48D8-8C8A-6F4EA2764E79Q37335637-0877217F-DAC9-4428-9C30-6233D00634AFQ37405140-1E74C015-1877-4F3F-8E9E-D2F8229E2DE5Q37607042-6B89AFCD-A254-4795-B223-0EF591CFAD14Q37634512-CB6AAA78-02AC-4418-8835-1707E5443E65Q37660709-ED66A378-2817-4980-9651-52EB1DC7D331Q37722849-BD82FEB9-FBEE-435E-942D-C0C03253D4D6Q38942113-0EC77C4B-B637-4B52-AA96-233A5D70337AQ39579026-71700143-CA16-4CAC-B260-1AF0E54F7CE8Q40187481-316363B3-F68A-4235-B721-E1A3179BFC40Q44797235-2A0F1C48-4A16-4148-BAA5-F8A2BCB34755Q46878731-2E9FF900-9553-44CF-92D1-FC46186A2010
P2860
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The cellular pharmacology of n ...... onship to clinical toxicities.
@ast
The cellular pharmacology of n ...... onship to clinical toxicities.
@en
type
label
The cellular pharmacology of n ...... onship to clinical toxicities.
@ast
The cellular pharmacology of n ...... onship to clinical toxicities.
@en
prefLabel
The cellular pharmacology of n ...... onship to clinical toxicities.
@ast
The cellular pharmacology of n ...... onship to clinical toxicities.
@en
P2093
P2860
P356
P1476
The cellular pharmacology of n ...... onship to clinical toxicities.
@en
P2093
Kenneth A Lichtenstein
Peter L Anderson
Thomas N Kakuda
P2860
P304
P356
10.1086/381678
P407
P577
2004-02-18T00:00:00Z